PC
DCPH

PointState Capital’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

PointState Capital’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-174,400
Closed -$6.86M – 193
2018
Q2 		$6.86M Buy
+174,400
New +$5.13M 0.08% 116

Other funds holding DCPH

NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PointState Capital's DCPH Position: Q3 2018 in Review

PointState Capital sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q3 2018, closing a stake of 174,400 shares — an estimated $6.86M sold.

PointState Capital first reported a position in DCPH in Q2 2018 and held it in 1 quarter. The position peaked at $6.86M in Q2 2018. 88 funds tracked by Wall St. Rank hold DCPH as of Q3 2018.

  • PointState Capital reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • PointState Capital sold 174,400 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q3 2018, an estimated $6.86M.
  • PointState Capital first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • PointState Capital's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $6.86M in Q2 2018.
  • 88 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q3 2018.

Based on PointState Capital's 13F filing for Q3 2018, filed 14 Nov 2018.